These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 2500386)

  • 1. Phase II evaluation of peroral carmofur, cyclophosphamide, and hexamethylmelamine as a second-line therapy in advanced epithelial ovarian carcinoma.
    Sipilä P; Kivinen S; Gröhn P; Vesala J; Heinonen E
    Gynecol Oncol; 1989 Jul; 34(1):27-9. PubMed ID: 2500386
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Chemotherapy in 143 advanced epithelial cancers of the ovary. Experience at the Hôtel-Dieu of Quebec and Hôpital Saint-Antoine (Paris)].
    de Gramont A; Drolet Y; Louvet C; Dray C; Krulik M; Pigné A; Lavoie A; Painchaud M; Blouin R; Tessier C
    J Gynecol Obstet Biol Reprod (Paris); 1986; 15(1):105-9. PubMed ID: 3084619
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Advanced ovarian cancer: long-term results of treatment with intensive cisplatin-based chemotherapy of brief duration.
    Hainsworth JD; Grosh WW; Burnett LS; Jones HW; Wolff SN; Greco FA
    Ann Intern Med; 1988 Feb; 108(2):165-70. PubMed ID: 3124679
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of hexamethylmelamine in the combination chemotherapy of advanced ovarian cancer: a comparison of hexamethylmelamine, cyclophosphamide, doxorubicin, and cisplatin (H-CAP) versus cyclophosphamide, doxorubicin, and cisplatin (CAP).
    Hainsworth JD; Jones HW; Burnett LS; Johnson DH; Greco FA
    Am J Clin Oncol; 1990 Oct; 13(5):410-5. PubMed ID: 2121019
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomized trial of initial therapy with melphalan versus cisplatin-based combination chemotherapy in patients with advanced ovarian carcinoma: initial and long term results--Eastern Cooperative Oncology Group Study E2878.
    Wadler S; Yeap B; Vogl S; Carbone P
    Cancer; 1996 Feb; 77(4):733-42. PubMed ID: 8616766
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term results of a cisplatin-containing combination chemotherapy regimen for the treatment of advanced ovarian carcinoma.
    Louie KG; Ozols RF; Myers CE; Ostchega Y; Jenkins J; Howser D; Young RC
    J Clin Oncol; 1986 Nov; 4(11):1579-85. PubMed ID: 3095501
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hexamethylmelamine-CAF (cyclophosphamide, methotrexate, and 5-FU) and cisplatin-CAF in refractory ovarian cancer.
    Sessa C; D'Incalci M; Valente I; Bolis G; Colombo N; Mangioni C
    Cancer Treat Rep; 1982 May; 66(5):1233-4. PubMed ID: 6805951
    [No Abstract]   [Full Text] [Related]  

  • 8. Hexamethylmelamine, methotrexate and 5-fluorouracil (HMF) for progressive ovarian carcinoma during therapy with cis-platinum, cyclophosphamide +/- doxorubicin.
    Carlson JA; Day TG; Botts B; Masterson BJ
    Gynecol Oncol; 1985 Oct; 22(2):189-94. PubMed ID: 3932141
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Six-drug chemotherapy (hexamethylmelamine, doxorubicin, cisplatin, cyclophosphamide, methotrexate, and 5-FU; CHAMP-5) for ovarian carcinoma: alternating sequences of combination regimens.
    Pasmantier MW; Coleman M; Silver RT; Ballard WP
    Cancer Treat Rep; 1985 Jun; 69(6):689-93. PubMed ID: 3926310
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The cyclophosphamide, hexamethylmelamine, 5 fluorouracil (CHF) regimen in the treatment of advanced and recurrent ovarian cancer.
    Posada JG; Marantz AB; Yeung KY; Smith FP; Delgado G; Edwards BK; Schein PS
    Gynecol Oncol; 1985 Jan; 20(1):23-31. PubMed ID: 3917421
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hexamethylmelamine, cyclophosphamide, adriamycin, cis-platinum chemotherapy as initial and second-line treatment of advanced ovarian carcinoma.
    Richman CM; Podczaski E; Weiser PA; Herbst AL
    Oncology; 1986; 43(1):12-7. PubMed ID: 3079898
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A randomized study of sequential versus alternating combination chemotherapy in advanced ovarian carcinoma.
    Lund B; Hansen M; Hansen HH; Thomsen HK; Sørensen BL; Nielsen NC; Lundvall F
    Ann Oncol; 1990; 1(2):134-40. PubMed ID: 2127690
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Chemotherapy of epithelial ovarian cancer: CHexUP versus thio-tepa].
    Wu BZ
    Zhonghua Fu Chan Ke Za Zhi; 1987 Jan; 22(1):5-8, 61. PubMed ID: 3109851
    [No Abstract]   [Full Text] [Related]  

  • 14. [Treatment of advanced ovarian cancer].
    de Gramont A; Krulik M; Pigne A; Brissaud P; Sirinelli A; Hubert D; Zylberait D; Debray J
    Sem Hop; 1984 Mar; 60(14):957-60. PubMed ID: 6326283
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Advanced ovarian cancer: brief intensive combination chemotherapy and second-look operation.
    Greco FA; Julian CG; Richardson RL; Burnett L; Hande KR; Oldham RK
    Obstet Gynecol; 1981 Aug; 58(2):199-205. PubMed ID: 6789265
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Chemotherapy of epithelial ovarian carcinoma].
    Bruntsch U; Gallmeier WM
    MMW Munch Med Wochenschr; 1983 Nov; 125(44):993-5. PubMed ID: 6417517
    [No Abstract]   [Full Text] [Related]  

  • 17. Treatment of advanced ovarian cancer with sequential combination chemotherapy.
    Griffin TW; Hunter RA; Cederbaum AI; Tak WK; Ward AD; Schwartz JH; Halpin TF; Strauss GM; Meyer RN; Liepman MK
    Cancer; 1987 Nov; 60(9):2150-5. PubMed ID: 2830953
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A comparison of hexamethylmelamine (altretamine), cyclophosphamide, doxorubicin, and cisplatin (H-CAP) vs. cyclophosphamide, doxorubicin, and cisplatin (CAP) in advanced ovarian cancer.
    Greco FA; Johnson DH; Hainsworth JD
    Cancer Treat Rev; 1991 Mar; 18 Suppl A():47-55. PubMed ID: 1904309
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recurrent ovarian carcinoma: retreatment utilizing combination chemotherapy including cis-diamminedichloroplatinum in patients previously responding to this agent.
    Seltzer V; Vogl S; Kaplan B
    Gynecol Oncol; 1985 Jun; 21(2):167-76. PubMed ID: 3921437
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HAC-Cytoxan (cyclophosphamide) chemotherapy for ovarian carcinoma. Alternating chemotherapy with intensification.
    Coleman M; Pasmantier MW; Silver RT
    Cancer; 1985 May; 55(10):2342-7. PubMed ID: 3921228
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.